Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07140315 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DK222 Study at Hopkins

StatusRecruiting
PhasePhase 1
Started2027-01-31
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later across 2 updates Jul 1, 2027 → Jan 31, 2028
See other at-risk trials from Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Amendment history

2026-09-30
Primary completion pushed: 2027-09-01 → 2028-01-31
Completion pushed: 2027-09-01 → 2028-01-31
2026-07-27
Study Status v7
Primary completion pushed: 2027-07-01 → 2027-09-01
Completion pushed: 2027-07-01 → 2027-09-01
Start date2026-07-01→2026-09-01
2026-05-21
Study Status v6
Primary completion pushed: 2027-05-01 → 2027-07-01
Completion pushed: 2027-05-01 → 2027-07-01
Start date2026-05-01→2026-07-01
2026-04-01
Study Status, Contacts/Locations v5
Recruitment opened
Study sitesdetails revised at 1 of 1 site
2026-03-11
Recruiting→Not Yet Recruiting Study Status, Contacts/Locations v4
Trial statusRecruiting→Not Yet Recruiting
Study sitesdetails revised at 1 of 1 site
Show 3 earlier versions
2026-03-04
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2027-02-01→2027-05-01
Completion date2027-02-01→2027-05-01
Start date2026-02-01→2026-05-01
Study sitesdetails revised at 1 of 1 site
2025-12-18
Study Status, Conditions v2
Start date2025-12-01→2026-02-01
2025-10-24
Study Status v1
Primary completion date2026-10-01→2027-02-01
Start date2025-10-01→2025-12-01
2025-08-18
Original filing
This Phase 1 clinical trial will test a new drug called \[18F\]DK222 in people with cancer. The goal is to see if the drug is safe, how it spreads through the body, how long it stays in the body, and how much radiation it gives off. \[18F\]DK222 is designed to attach strongly and specifically to a protein called PD-L1, which helps cancer hide from the immune system. This is a first in human study to collect preliminary safety and toxicity data of \[18F\]DK222.
Trial Details
NCT Number NCT07140315
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions Non-Small Cell Lung Cancer, Urothelial Cancer
Enrollment 6 participants
Start Date 2027-01-31
Primary Completion 2028-01-31 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-29